Tag: GeNeuro
The shareholders of GeNeuro approve all the resolutions proposed at the Extraordinary General Meeting of March 18, 2024 – 03/20/2024 at 6:30 p.m.
81.4% of the company’s share capital was represented at the general meeting and the resolutions were all approved unanimouslyDownload the press release in PDF Geneva, Switzerland, March 20, 2024 –…
Geneuro launches a capital increase of some 5 million euros – 02/01/2024 at 6:31 p.m.
(AOF) – Geneuro announces the launch of a capital increase for an indicative amount of 5 million euros, with elimination of shareholders’ preferential subscription rights through a private placement reserved…
Geneuro launches a capital increase of around 5 million euros
(AOF) – Geneuro announces the launch of a capital increase for an indicative amount of 5 million euros, with elimination of shareholders’ preferential subscription rights through a private placement reserved…
GeNeuro: Invesco no longer holds shares
JN.L. Published on 01/08/2024 at 2:33 p.m. Photo credit © Euronext (Boursier.com) — By mail received on…
GeNeuro: Citigroup Global Markets Limited increases to 8.56% of the capital
JN.L. Published on 01/05/2024 at 10:05 a.m. Photo credit © Euronext (Boursier.com) — By letter received on…
GeNeuro: appointment of a new medical director – 01/08/2024 at 07:08
(CercleFinance.com) – GeNeuro announces the appointment of Anke Post as chief medical officer, effective last Friday, following the retirement of David Leppert, who had held this position since April 2020.…
GeNeuro: appointment of a new medical director
(CercleFinance.com) – GeNeuro announces the appointment of Anke Post as chief medical officer, effective last Friday, following the retirement of David Leppert, who had held this position since April 2020.…
GeNeuro appoints Anke Post as Medical Director
(Boursier.com) — GeNeuro a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and post-acute sequelae of COVID-19…
GeNeuro appoints Anke Post as Medical Director, following the retirement of David Leppert, who becomes a consultant for GeNeuro – 01/05/2024 at 6:00 p.m.
Geneva, Switzerland, January 5, 2024 – 6:00 p.m. CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), biopharmaceutical company whose objective is to stop the progression of neurodegenerative and autoimmune diseases…
Anke Post appointed Medical Director of Geneuro – 01/05/2024 at 6:19 p.m.
(AOF) – Geneuro, a biopharmaceutical company, has appointed Anke Post as Chief Medical Officer, following the retirement of David Leppert, Medical Director since April 2020. Anke Post will bring her…
Anke Post appointed Medical Director of Geneuro
(AOF) – Geneuro, a biopharmaceutical company, has appointed Anke Post as Chief Medical Officer, following the retirement of David Leppert, Medical Director since April 2020. Anke Post will bring her…
Geneuro: continuation of the long Covid trial after advice from the supervisory committee
(AOF) – GeNeuro announces today that the Independent Data Monitoring Committee of the trial evaluating its product temelimab in Long Covid has recommended “continuing the trial without any modification”. The…